Galera Therapeutics, Inc.
GRTXDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563577
Galera Therapeutics, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Aug 5, 2026; 36 institutions reported holding it in 13F filings for Q1 2024, worth $1.37M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 36
- Q1 2024, −1 vs. previous quarter
- 13F value
- $1.37M
- Reported value at the end of Q1 2024
- Superinvestors holding
- 0
- At the end of Q1 2024
Superinvestors holding GRTX, Q1 2024
No superinvestor reported holding GRTX at the end of Q1 2024.
Latest insider trades
Open-market purchases and sales by Galera Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 (view filing)4:42 PM ET | Nov 20 | 4 days | Sorensen MelPresident and CEO | SSale | −70.0K | $0.0201 | −$1.41K | −26.4%195.0K after | |
| Jan 2, 2025 (view filing)4:12 PM ET | Dec 30, 2024 | 3 days | Chang Nancy TDirector, 10% Owner | PPurchase | +7.64M | $0.0654 | +$500.0K | New position7.64M after | |
| Aug 20, 2024 (view filing)4:45 PM ET | Aug 16 | 4 days | Sorensen MelPresident and CEO | SSale | −67.0K | $0.072 | −$4.83K | −20.2%265.0K after | |
| May 1, 2024 (view filing)5:02 PM ET | Apr 17, 2014-Apr 19, 2024 | 3,667 days | Schneid Yair10% Owner | PPurchase | +2.78M | $0.2124 | +$590.4K | +34.6%10.8M after | Amended21 lots |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Bachleda MarkChief Commercial Officer | PPurchase | +11.0K | $2.25 | +$24.8K | New position11.0K after | |
| Mar 14, 2023 (view filing) | Mar 10 | 4 days | Sorensen MelPresident and CEO | PPurchase | +100.0K | $1.68 | +$168.0K | +43.1%332.0K after | |
| Mar 14, 2023 (view filing) | Mar 13 | 1 day | Degnan ChrisChief Financial Officer | PPurchase | +10.0K | $1.96 | +$19.6K | New position10.0K after | |
| Dec 20, 2021 (view filing) | Dec 17 | 3 days | West LindaDirector | PPurchase | +20.0K | $2.74 | +$54.8K | +50.0%60.0K after | |
| Sep 3, 2021 (view filing) | Sep 1 | 2 days | Holmlund Jon TChief Medical Officer | SSale | −47.8K | $8.47 | −$404.5K | −100.0%0 after |
Top 10 13F holders, Q1 2024
The largest institutional positions in Galera Therapeutics, Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gsa Capital Partners LLP | 3,632,627 | $509.0K | 0.04% | −259,934−6.7% | Reduced |
| Blackstone Group Inc. | 1,678,984 | $235.1K | 0.00% | 00.0% | Unchanged |
| Standard Life Aberdeen plc | 898,374 | $125.8K | 0.00% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 613,223 | $85.9K | 0.08% | 00.0% | Unchanged |
| Vanguard Group Inc | 448,330 | $62.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 440,349 | $61.7K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 357,192 | $50.0K | 0.00% | −430−0.1% | Reduced |
| Atom Investors LP | 356,204 | $49.9K | 0.01% | +356,204 | New |
| UBS Group AG | 293,502 | $41.1K | 0.00% | +281,287+2,302.8% | Added |
| Susquehanna International Group, LLP | 286,180 | $40.1K | 0.00% | +286,180 | New |